Overview

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

Status:
Active, not recruiting

Trial end date:
2024-09-30

Target enrollment:
0

Participant gender:
All

Summary

Breast cancer, a leading cause of cancer-related mortality in women worldwide, has spurred the investigation of novel therapeutic approaches. Pentoxifylline (PTX), a synthetic methylxanthine derivative, has shown promise in preclinical studies when combined with conventional anticancer drugs. This study aims to assess PTX's impact when added to neoadjuvant chemotherapy protocols in breast cancer patients, with the goal of improving treatment outcomes and reducing associated toxicities.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Mansoura University

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Pentoxifylline
Taxane

Criteria

Inclusion Criteria:

- Adult female patients >18 years old with histologic confirmation of invasive breast
cancer

- Planned to administer neoadjuvant chemotherapy protocol comprised of doxorubicin/
cyclophosphamide followed by paclitaxel (AC/T)

- Adequate hepatic, renal, and bone marrow functions

Exclusion Criteria:

- Patients on treatment regimen of phosphodiesterase inhibitors

- Patients who are taking antiplatelet or anticoagulant treatment

- Patients who are allergic to phosphodiesterase inhibitors

- History of recent hemorrhagic events

- Active peptic ulcer